TD Asset Management Inc Raises Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

TD Asset Management Inc boosted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 7.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 178,072 shares of the biopharmaceutical company’s stock after acquiring an additional 12,400 shares during the period. TD Asset Management Inc’s holdings in Agios Pharmaceuticals were worth $5,218,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of AGIO. Jefferies Financial Group Inc. purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $49,290,000. Adage Capital Partners GP L.L.C. purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $9,957,000. Paradigm Biocapital Advisors LP purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $9,084,000. Deutsche Bank AG grew its stake in Agios Pharmaceuticals by 39.7% during the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company’s stock valued at $30,732,000 after acquiring an additional 265,637 shares in the last quarter. Finally, Casdin Capital LLC purchased a new position in Agios Pharmaceuticals during the fourth quarter valued at approximately $8,215,000.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wall Street Zen cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 19th. Bank of America cut their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research note on Tuesday, July 22nd. Finally, Scotiabank cut their price target on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research note on Monday, July 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.33.

Agios Pharmaceuticals Trading Down 6.0%

NASDAQ AGIO opened at $35.00 on Friday. Agios Pharmaceuticals, Inc. has a 12 month low of $23.42 and a 12 month high of $62.58. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of 3.18 and a beta of 0.80. The company’s 50 day moving average is $35.69 and its two-hundred day moving average is $32.57.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.39% and a net margin of 1,590.42%. The firm had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. Sell-side analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Insider Activity at Agios Pharmaceuticals

In other news, insider Tsveta Milanova sold 2,770 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $92,905.80. Following the sale, the insider owned 26,122 shares in the company, valued at $876,131.88. This trade represents a 9.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David Scadden sold 1,400 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $40.00, for a total transaction of $56,000.00. Following the sale, the director owned 17,603 shares in the company, valued at approximately $704,120. The trade was a 7.37% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 46,363 shares of company stock worth $1,619,654 in the last 90 days. Insiders own 4.30% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.